IN2014DN09782A - - Google Patents
Info
- Publication number
- IN2014DN09782A IN2014DN09782A IN9782DEN2014A IN2014DN09782A IN 2014DN09782 A IN2014DN09782 A IN 2014DN09782A IN 9782DEN2014 A IN9782DEN2014 A IN 9782DEN2014A IN 2014DN09782 A IN2014DN09782 A IN 2014DN09782A
- Authority
- IN
- India
- Prior art keywords
- glp
- analogues
- gly2
- gastro
- ameliorating
- Prior art date
Links
- 230000000694 effects Effects 0.000 abstract 2
- 101100505076 Caenorhabditis elegans gly-2 gene Proteins 0.000 abstract 1
- 102100025101 GATA-type zinc finger protein 1 Human genes 0.000 abstract 1
- 101710198884 GATA-type zinc finger protein 1 Proteins 0.000 abstract 1
- DTHNMHAUYICORS-KTKZVXAJSA-N Glucagon-like peptide 1 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 230000002496 gastric effect Effects 0.000 abstract 1
- 229940121355 glucagon like peptide 2 (glp-2) analogues Drugs 0.000 abstract 1
- YMAWOPBAYDPSLA-UHFFFAOYSA-N glycylglycine Chemical compound [NH3+]CC(=O)NCC([O-])=O YMAWOPBAYDPSLA-UHFFFAOYSA-N 0.000 abstract 1
- 238000011321 prophylaxis Methods 0.000 abstract 1
- 238000006467 substitution reaction Methods 0.000 abstract 1
- 238000011282 treatment Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/605—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/22—Urine; Urinary tract, e.g. kidney or bladder; Intraglomerular mesangial cells; Renal mesenchymal cells; Adrenal gland
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/48—Reproductive organs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/48—Reproductive organs
- A61K35/54—Ovaries; Ova; Ovules; Embryos; Foetal cells; Germ cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/63—Arthropods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/63—Arthropods
- A61K35/64—Insects, e.g. bees, wasps or fleas
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Zoology (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Cell Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Developmental Biology & Embryology (AREA)
- Insects & Arthropods (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Biotechnology (AREA)
- Virology (AREA)
- Reproductive Health (AREA)
- Biophysics (AREA)
- Toxicology (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261642447P | 2012-05-03 | 2012-05-03 | |
| US201361785852P | 2013-03-14 | 2013-03-14 | |
| PCT/EP2013/059320 WO2013164484A1 (en) | 2012-05-03 | 2013-05-03 | Glucagon-like-peptide-2 (glp-2) analogues |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2014DN09782A true IN2014DN09782A (enExample) | 2015-07-31 |
Family
ID=48428462
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN9782DEN2014 IN2014DN09782A (enExample) | 2012-05-03 | 2014-11-19 |
Country Status (13)
| Country | Link |
|---|---|
| US (3) | US9453064B2 (enExample) |
| EP (1) | EP2844670B1 (enExample) |
| JP (1) | JP6298044B2 (enExample) |
| KR (1) | KR20150006052A (enExample) |
| CN (1) | CN104540850B (enExample) |
| AU (1) | AU2013255752B2 (enExample) |
| BR (1) | BR112014027345A2 (enExample) |
| CA (1) | CA2872315A1 (enExample) |
| EA (1) | EA028929B1 (enExample) |
| IN (1) | IN2014DN09782A (enExample) |
| MX (1) | MX356958B (enExample) |
| TR (1) | TR201802689T4 (enExample) |
| WO (1) | WO2013164484A1 (enExample) |
Families Citing this family (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2007319066B2 (en) | 2006-11-08 | 2013-09-19 | Zealand Pharma A/S | Selective glucagon-like-peptide-2 (GLP-2) analogues |
| AU2013255752B2 (en) | 2012-05-03 | 2017-11-09 | Zealand Pharma A/S | Glucagon-like-peptide-2 (GLP-2) analogues |
| IN2015DN00544A (enExample) | 2012-07-23 | 2015-06-26 | Zealand Pharma As | |
| UA116217C2 (uk) | 2012-10-09 | 2018-02-26 | Санофі | Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону |
| RU2652783C2 (ru) | 2012-12-21 | 2018-05-03 | Санофи | Двойные агонисты glp1/gip или тройные агонисты glp1/gip/глюкагона |
| KR102394515B1 (ko) | 2013-10-17 | 2022-05-09 | 질랜드 파마 에이/에스 | 아실화된 글루카곤 유사체 |
| US9988429B2 (en) | 2013-10-17 | 2018-06-05 | Zealand Pharma A/S | Glucagon analogues |
| MX2016005556A (es) | 2013-11-06 | 2016-07-15 | Zealand Pharma As | Compuestos agonistas duales de gip-glp-1 y procedimientos. |
| KR102310392B1 (ko) | 2013-11-06 | 2021-10-13 | 질랜드 파마 에이/에스 | 글루카곤-ｇｌｐ-1-ｇｉｐ 삼원 효능제 화합물 |
| EP3080150B1 (en) | 2013-12-13 | 2018-08-01 | Sanofi | Exendin-4 peptide analogues as dual glp-1/gip receptor agonists |
| WO2015086730A1 (en) | 2013-12-13 | 2015-06-18 | Sanofi | Non-acylated exendin-4 peptide analogues |
| EP3080149A1 (en) | 2013-12-13 | 2016-10-19 | Sanofi | Dual glp-1/glucagon receptor agonists |
| EP3080154B1 (en) | 2013-12-13 | 2018-02-07 | Sanofi | Dual glp-1/gip receptor agonists |
| EP3080155A1 (en) * | 2013-12-13 | 2016-10-19 | Sanofi | Exendin-4 peptide analogues as dual glp-1/glucagon receptor agonists |
| TW201625669A (zh) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | 衍生自艾塞那肽－４（Ｅｘｅｎｄｉｎ－４）之肽類雙重ＧＬＰ－１／升糖素受體促效劑 |
| TW201625670A (zh) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | 衍生自ｅｘｅｎｄｉｎ－４之雙重ｇｌｐ－１／升糖素受體促效劑 |
| TW201625668A (zh) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | 作為胜肽性雙重ｇｌｐ－１／昇糖素受體激動劑之艾塞那肽－４衍生物 |
| US9932381B2 (en) | 2014-06-18 | 2018-04-03 | Sanofi | Exendin-4 derivatives as selective glucagon receptor agonists |
| DK3212218T3 (da) | 2014-10-29 | 2021-08-30 | Zealand Pharma As | GIP-agonistforbindelser og fremgangsmåder |
| US20180280480A1 (en) * | 2014-10-31 | 2018-10-04 | Gubra Aps | Compositions and peptides having dual glp-1r and glp-2r agonist activity |
| EP3283507B8 (en) | 2015-04-16 | 2019-11-13 | Zealand Pharma A/S | Acylated glucagon analogue |
| AR105319A1 (es) | 2015-06-05 | 2017-09-27 | Sanofi Sa | Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico |
| AR105284A1 (es) | 2015-07-10 | 2017-09-20 | Sanofi Sa | Derivados de exendina-4 como agonistas peptídicos duales específicos de los receptores de glp-1 / glucagón |
| LT3393496T (lt) | 2015-12-23 | 2023-12-11 | The Johns Hopkins University | Ilgo veikimo glp-1r agonistas, kaip neurologinių ir neurodegeneracinių būklių terapija |
| JP6700150B2 (ja) * | 2016-10-03 | 2020-05-27 | 東京エレクトロン株式会社 | パーティクル捕集装置、パーティクル捕集方法、およびパーティクル捕集システム |
| BR112019010624A2 (pt) * | 2016-12-09 | 2019-10-22 | Zealand Pharma As | agonistas duplos de glp-1/glp-2 acilados e composição |
| WO2018104558A1 (en) | 2016-12-09 | 2018-06-14 | Zealand Pharma A/S | Acylated glp-1/glp-2 dual agonists |
| RU2756011C2 (ru) * | 2016-12-09 | 2021-09-24 | Зилэнд Фарма А/С | Glp-1/glp-2 двойные агонисты |
| WO2018103868A1 (en) | 2016-12-09 | 2018-06-14 | Zealand Pharma A/S | Acylated glp-1/glp-2 dual agonists |
| WO2018104559A1 (en) | 2016-12-09 | 2018-06-14 | Zealand Pharma A/S | Glp-1/glp-2 dual agonists |
| IL299864B2 (en) * | 2017-06-16 | 2024-06-01 | Zealand Pharma As | Dosage regimes for the administration of glucagon-like-peptide-2 (glp-2) analogues |
| GB201710822D0 (en) * | 2017-07-05 | 2017-08-16 | Zealand Pharma As | Methods and medical uses relating to the treatment of hypoglycaemia |
| WO2019090209A1 (en) | 2017-11-06 | 2019-05-09 | Shire-Nps Pharmaceuticals, Inc. | Glp-2 analogs and peptibodies for administration before during, or after surgery |
| WO2020020904A1 (en) | 2018-07-23 | 2020-01-30 | Zealand Pharma A/S | Therapeutic uses of glp-2 agonists |
| KR20210126088A (ko) | 2019-02-11 | 2021-10-19 | 옵코 바이오로직스 리미티드 | 지속성 glp-2 유사체 |
| AU2020293576B2 (en) | 2019-06-14 | 2025-04-10 | Zealand Pharma A/S | Pharmaceutical parenteral composition of dual GLP1/2 agonist |
| CA3156985A1 (en) | 2019-10-07 | 2021-04-15 | Kallyope, Inc. | Gpr119 agonists |
| CN111329995B (zh) * | 2020-02-18 | 2022-11-11 | 河南中医药大学 | Glp-2类似物在制备防治pd药物中的应用及防治pd的药物 |
| JP7745559B2 (ja) | 2020-02-28 | 2025-09-29 | キャリーオペ，インク． | Ｇｐｒ４０アゴニスト |
| JP2023520498A (ja) * | 2020-04-03 | 2023-05-17 | ハンミ ファーマシューティカル カンパニー リミテッド | Ｇｌｐ－２誘導体またはその持続型結合体を含む放射線療法、化学療法、またはこれらの組合わせにより誘発された粘膜炎の予防または治療用薬学的組成物 |
| CA3178994A1 (en) | 2020-05-19 | 2021-11-25 | Iyassu Sebhat | Ampk activators |
| CN116157413A (zh) | 2020-06-09 | 2023-05-23 | 维克蒂生物股份有限公司 | 阿普拉鲁肽的制造、配制和给药 |
| CN116390925A (zh) | 2020-06-26 | 2023-07-04 | 卡尔优普公司 | Ampk活化剂 |
| AU2023346836A1 (en) | 2022-09-19 | 2025-03-20 | Zealand Pharma A/S | Combination therapy |
| CN116478269A (zh) * | 2023-04-28 | 2023-07-25 | 成都奥达生物科技有限公司 | 一种长效替度鲁肽化合物 |
| CN118146350B (zh) * | 2024-03-13 | 2024-10-22 | 北京泽勤生物医药有限公司 | Glp-2肽类似物的制备方法及应用 |
Family Cites Families (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ZA811368B (en) | 1980-03-24 | 1982-04-28 | Genentech Inc | Bacterial polypedtide expression employing tryptophan promoter-operator |
| JP2961045B2 (ja) | 1993-02-24 | 1999-10-12 | 日清製粉株式会社 | 腸管粘膜増強促進剤 |
| US6184208B1 (en) | 1994-06-29 | 2001-02-06 | Immunotech Developments Inc. | Peptide, a method for its preparation and a pharmaceutical composition containing the peptide |
| US5990077A (en) | 1995-04-14 | 1999-11-23 | 1149336 Ontario Inc. | Glucagon-like peptide-2 and its therapeutic use |
| US5834428A (en) | 1995-04-14 | 1998-11-10 | 1149336 Ontario Inc. | Glucagon-like peptide-2 and its therapeutic use |
| US6184201B1 (en) | 1995-04-14 | 2001-02-06 | Nps Allelix Corp. | Intestinotrophic glucagon-like peptide-2 analogs |
| US5789379A (en) | 1995-04-14 | 1998-08-04 | Allelix Biopharmaceutical Inc. | Glucagon-like peptide-2 analogs |
| US5912229A (en) | 1996-03-01 | 1999-06-15 | Novo Nordisk Als | Use of a pharmaceutical composition comprising an appetite-suppressing peptide |
| WO1997031943A1 (en) | 1996-03-01 | 1997-09-04 | Novo Nordisk A/S | Use of a pharmaceutical composition comprising an appetite-suppressing peptide |
| CA2251576C (en) | 1996-04-12 | 2012-08-21 | 1149336 Ontario Inc. | Glucagon-like peptide-2 analogs |
| US5994500A (en) | 1996-07-19 | 1999-11-30 | 1149336 Ontario Inc. | Antagonists of intestinotrophic GLP-2 peptides |
| ATE356830T1 (de) | 1996-08-30 | 2007-04-15 | Novo Nordisk As | Glp-1 derivate |
| US20020025933A1 (en) | 1996-08-30 | 2002-02-28 | Knudsen Liselotte Bjerre | GLP-2 derivatives |
| AU723268B2 (en) | 1996-09-09 | 2000-08-24 | Zealand Pharma A/S | Improved solid-phase peptide synthesis and agent for use in such synthesis |
| US5952301A (en) | 1996-12-10 | 1999-09-14 | 1149336 Ontario Inc. | Compositions and methods for enhancing intestinal function |
| CA2236519C (en) | 1997-05-02 | 2011-09-13 | 1149336 Ontario Inc. | Methods of enhancing functioning of the large intestine |
| US6051557A (en) | 1997-05-16 | 2000-04-18 | 1149336 Ontario Inc. | Methods of enhancing functioning of the upper gastrointestinal tract |
| DE69819488T2 (de) | 1997-05-16 | 2004-08-26 | 1149336 Ontario Inc., Toronto | Verwendung von glp-2 agonisten zur verbesserung der wirkung des oberen gastrointestinaltraktes |
| CA2755452C (en) | 1998-02-02 | 2013-09-10 | Trustees Of Tufts College | Method of regulating glucose metabolism, and reagents related thereto |
| AU757658B2 (en) | 1998-03-09 | 2003-02-27 | Zealand Pharma A/S | Pharmacologically active peptide conjugates having a reduced tendency towards enzymatic hydrolysis |
| WO1999058144A1 (en) | 1998-05-11 | 1999-11-18 | 1149336 Ontario Inc. | Methods of enhancing functioning of the large intestine |
| US6451987B1 (en) | 1999-03-15 | 2002-09-17 | Novo Nordisk A/S | Ion exchange chromatography of proteins and peptides |
| CN1344248A (zh) | 1999-03-17 | 2002-04-10 | 诺沃挪第克公司 | 肽的酰化方法和新酰化剂 |
| EP1076066A1 (en) | 1999-07-12 | 2001-02-14 | Zealand Pharmaceuticals A/S | Peptides for lowering blood glucose levels |
| WO2001041779A2 (en) | 1999-12-08 | 2001-06-14 | 1149336 Ontario Inc. | Combined use of glp-2 receptor agonist and chemotherapeutic agent in treatment |
| US7371721B2 (en) | 2000-09-18 | 2008-05-13 | Sanos Bioscience A/S | Use of GLP-2 and related compounds for the treatment, prevention, diagnosis, and prognosis of bone-related disorders and calcium homeostasis related syndromes |
| US7186683B2 (en) | 2000-09-18 | 2007-03-06 | Sanos Bioscience A/S | Use of GLP for the treatment, prevention, diagnosis, and prognosis of bone-related and nutrition-related disorders |
| EP1326630B1 (en) | 2000-09-18 | 2008-05-28 | Sanos Bioscience A/S | Use of glp-2 peptides |
| WO2002066062A2 (en) | 2001-02-01 | 2002-08-29 | Drucker Daniel J | Enhancement of glp-2 activity |
| CA2436399A1 (en) | 2001-02-16 | 2002-08-29 | Conjuchem Inc. | Long lasting glucagon-like peptide 2 (glp-2) for the treatment of gastrointestinal diseases and disorders |
| EP1542712A2 (en) | 2001-06-01 | 2005-06-22 | Eli Lilly And Company | Glp-1 formulations with protracted time action |
| WO2004035624A2 (en) | 2002-10-14 | 2004-04-29 | Novo Nordisk A/S | Glucagon - like peptide - 2 variants |
| CN1705681A (zh) * | 2002-10-14 | 2005-12-07 | 诺沃挪第克公司 | Glp－2化合物、制剂及其用途 |
| JP2006517389A (ja) * | 2002-10-14 | 2006-07-27 | ノボ ノルディスク アクティーゼルスカブ | Ｇｌｐ−２化合物、製剤、及びそれらの使用 |
| EP1670515A2 (en) | 2003-09-19 | 2006-06-21 | Novo Nordisk A/S | Albumin-binding derivatives of therapeutic peptides |
| WO2005082404A2 (en) * | 2004-02-27 | 2005-09-09 | Novo Nordisk A/S | Glp-2 derivatives modified by lipophilic substituents |
| JP5197012B2 (ja) | 2004-11-01 | 2013-05-15 | エヌピーエス ファーマシューティカルズ インコーポレイテッド | 大腸連続性を伴う短腸症候群患者の治療 |
| KR101242951B1 (ko) | 2005-05-04 | 2013-03-13 | 질랜드 파마 에이/에스 | 글루카곤 유사 펩티드-2(ｇｌｐ-2) 유사체 |
| AU2007319066B2 (en) | 2006-11-08 | 2013-09-19 | Zealand Pharma A/S | Selective glucagon-like-peptide-2 (GLP-2) analogues |
| UA104605C2 (uk) * | 2008-12-15 | 2014-02-25 | Зіленд Фарма А/С | Аналоги глюкагону |
| AR081975A1 (es) * | 2010-06-23 | 2012-10-31 | Zealand Pharma As | Analogos de glucagon |
| WO2012158965A2 (en) * | 2011-05-18 | 2012-11-22 | Mederis Diabetes, Llc | Improved peptide pharmaceuticals for insulin resistance |
| AU2013255752B2 (en) | 2012-05-03 | 2017-11-09 | Zealand Pharma A/S | Glucagon-like-peptide-2 (GLP-2) analogues |
-
2013
- 2013-05-03 AU AU2013255752A patent/AU2013255752B2/en not_active Ceased
- 2013-05-03 CN CN201380029907.4A patent/CN104540850B/zh not_active Expired - Fee Related
- 2013-05-03 WO PCT/EP2013/059320 patent/WO2013164484A1/en not_active Ceased
- 2013-05-03 TR TR2018/02689T patent/TR201802689T4/tr unknown
- 2013-05-03 EP EP13721953.1A patent/EP2844670B1/en active Active
- 2013-05-03 US US14/398,297 patent/US9453064B2/en active Active
- 2013-05-03 MX MX2014013319A patent/MX356958B/es active IP Right Grant
- 2013-05-03 EA EA201491934A patent/EA028929B1/ru not_active IP Right Cessation
- 2013-05-03 JP JP2015509462A patent/JP6298044B2/ja not_active Expired - Fee Related
- 2013-05-03 BR BR112014027345A patent/BR112014027345A2/pt not_active Application Discontinuation
- 2013-05-03 CA CA2872315A patent/CA2872315A1/en not_active Abandoned
- 2013-05-03 KR KR1020147033951A patent/KR20150006052A/ko not_active Abandoned
-
2014
- 2014-11-19 IN IN9782DEN2014 patent/IN2014DN09782A/en unknown
-
2016
- 2016-08-16 US US15/238,126 patent/US9969787B2/en not_active Expired - Fee Related
-
2018
- 2018-04-11 US US15/950,235 patent/US10253080B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| AU2013255752A1 (en) | 2014-12-18 |
| BR112014027345A2 (pt) | 2019-09-03 |
| US9453064B2 (en) | 2016-09-27 |
| AU2013255752B2 (en) | 2017-11-09 |
| KR20150006052A (ko) | 2015-01-15 |
| JP2015517299A (ja) | 2015-06-22 |
| JP6298044B2 (ja) | 2018-03-20 |
| US9969787B2 (en) | 2018-05-15 |
| EP2844670B1 (en) | 2017-12-06 |
| MX2014013319A (es) | 2015-07-06 |
| CN104540850A (zh) | 2015-04-22 |
| CN104540850B (zh) | 2018-05-18 |
| CA2872315A1 (en) | 2013-11-07 |
| HK1208238A1 (en) | 2016-02-26 |
| EA028929B1 (ru) | 2018-01-31 |
| US20150125431A1 (en) | 2015-05-07 |
| WO2013164484A1 (en) | 2013-11-07 |
| US10253080B2 (en) | 2019-04-09 |
| EA201491934A1 (ru) | 2015-07-30 |
| US20180298077A1 (en) | 2018-10-18 |
| US20160355563A1 (en) | 2016-12-08 |
| TR201802689T4 (tr) | 2018-03-21 |
| EP2844670A1 (en) | 2015-03-11 |
| MX356958B (es) | 2018-06-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IN2014DN09782A (enExample) | ||
| PH12015502042A1 (en) | Use of linagliptin in cardio-and renoprotective antidiabetic therapy | |
| PH12014501702A1 (en) | Imidazopyrrolidinone compounds | |
| PH12015500115A1 (en) | Glucagon analogues | |
| NZ709392A (en) | Synergistic bacterial compositions and methods of production and use thereof | |
| MX2011007930A (es) | Conjugados de insulina cristalina. | |
| PH12014502452A1 (en) | Gip-glp-1 dual agonist compounds and methods | |
| MX2016005556A (es) | Compuestos agonistas duales de gip-glp-1 y procedimientos. | |
| EP4406593A3 (en) | Use of long-acting glp-1 peptides | |
| MX356728B (es) | Combinación farmacéutica para usar en el tratamiento de pacientes que padecen diabetes de tipo 2. | |
| MX2015008114A (es) | Derivados de exendina-4. | |
| MY170713A (en) | Treatment protocol of diabetes type 2 | |
| MX2013015168A (es) | Co-agonista del receptor de glucagon/glp-1. | |
| PH12013502671A1 (en) | Glucagon/glp-1 receptor co-agonists | |
| MX2014015423A (es) | Analogos de peptido de exedina-4. | |
| MX2012004078A (es) | Compuestos y composiciones como moduladores de la actividad de gpr119. | |
| MX2014008705A (es) | Compuestos tricíclicos de sulfona y métodos para elaborarlos y utilizarlos. | |
| MX366090B (es) | Combinación farmacéutica para usarse en mejorar la tolerancia a la glucosa en pacientes que padecen diabetes de tipo 2. | |
| IL235484A0 (en) | Glucokinase-activating preparations for the treatment of diabetes | |
| MX2013011124A (es) | Compuestos para el tratamiento del sindrome metabolico. | |
| BR112013011259A2 (pt) | condições de tratamento associadas com nível aumentado de eotaxina com 25-hidroxivitamina d3 | |
| MX354598B (es) | Uso de neuregulina para tratar lesion de nervio periferico. | |
| MX2016006603A (es) | Compuestos piperidinicos con actividad multimodal contra el dolor. | |
| IN2012DN00549A (enExample) | ||
| AU2013298343A8 (en) | Targeted oesophageal administration of Zn-alpha2-glycoproteins (ZAG), methods and formulations thereof |